Heparin neutralisation by recombinant platelet factor 4 and heparinase
Publication
, Journal Article
Levy, JH; Michelsen, LG
Published in: Anaesthetic Pharmacology Review
January 1, 1995
Our clinical armamentarium requires alternatives to protamine. Initial human data with rPF4 reveal an effective safe agent. The adverse haemodynamic effects in lambs may derive from species variability, or may represent a cause for concern. Data from human studies must be collected, especially during cardiac surgery. Currently, rPF4 appears to represent an important alternative to protamine for the reversal of heparin anticoagulation. Heparinase effectively and safely neutralises heparin anticoagulation in animal models. Additional human data will determine its applicability to clinical medicine.
Duke Scholars
Published In
Anaesthetic Pharmacology Review
ISSN
0966-7954
Publication Date
January 1, 1995
Volume
3
Issue
2
Start / End Page
112 / 117
Citation
APA
Chicago
ICMJE
MLA
NLM
Levy, J. H., & Michelsen, L. G. (1995). Heparin neutralisation by recombinant platelet factor 4 and heparinase. Anaesthetic Pharmacology Review, 3(2), 112–117.
Levy, J. H., and L. G. Michelsen. “Heparin neutralisation by recombinant platelet factor 4 and heparinase.” Anaesthetic Pharmacology Review 3, no. 2 (January 1, 1995): 112–17.
Levy JH, Michelsen LG. Heparin neutralisation by recombinant platelet factor 4 and heparinase. Anaesthetic Pharmacology Review. 1995 Jan 1;3(2):112–7.
Levy, J. H., and L. G. Michelsen. “Heparin neutralisation by recombinant platelet factor 4 and heparinase.” Anaesthetic Pharmacology Review, vol. 3, no. 2, Jan. 1995, pp. 112–17.
Levy JH, Michelsen LG. Heparin neutralisation by recombinant platelet factor 4 and heparinase. Anaesthetic Pharmacology Review. 1995 Jan 1;3(2):112–117.
Published In
Anaesthetic Pharmacology Review
ISSN
0966-7954
Publication Date
January 1, 1995
Volume
3
Issue
2
Start / End Page
112 / 117